Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Status:
Terminated
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the antitumor efficacy and the safety of MK 2206 in
patients with relapsed or refractory diffuse large B cell lymphoma.